ELVN250117C15000
- 0.00
- 0.000.00%
Enliven Therapeutics Newsroom
BTIG Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $42
JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $36
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38
JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $36
A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $36 to $40
Enliven Therapeutics Analyst Ratings
Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40
TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating
Enliven Therapeutics Price Target Announced at $36.00/Share by Jones Trading
JonesTrading Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $36
Enliven Therapeutics Analyst Ratings
H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $37
Enliven Therapeutics Garners Buy Rating on Robust Clinical Results and Safety Profile for Lead CML Drug Candidate
Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $39
TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Enliven Therapeutics (ELVN)
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38
Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $39
H.C. Wainwright Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $37
HC Wainwright & Co. Initiates Coverage On Enliven Therapeutics With Buy Rating, Announces Price Target of $37